I take it u mean OSL not RAP? yes i heard same, md did say sales imminent More important he also said reimbursement would happen this year
as the major euro markets like UK, Germany are mostly public funded health systems, getting device reimbursed is essential otherwise I can’t see how this can be commercially successful there. But It’s likely the current low level evidence could be barrier to broad funding or getting top price imho.
I looked back at the announcement late Aug ‘18 where Osl said iqvia were appointed market access consultants to manage reimbursement strategy in Europe. It was quite detailed on what iqvia were to do So assuming that work was done OSL have had years to prep, they would have known exactly what to do on day 1 after CE granted. 6 months on from that there has been nothing concrete communicated on this. If by Jan still nothing, got to worry. MD needs to explain at AGM what is happening with this.
OSL Price at posting:
12.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)